Shareholders in Standard BioTools (NASDAQ:LAB) are in the red if they invested three years ago [Yahoo! Finance]
Standard BioTools Inc. (LAB)
Company Research
Source: Yahoo! Finance
Standard BioTools Inc. NASDAQ:LAB ) have had an unfortunate run in the last three years. Sadly for them, the share price is down 69% in that time. And more recent buyers are having a tough time too, with a drop of 27% in the last year. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. Standard BioTools wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. Over the last three years, Standard BioTools' revenue dropped 5.6% per year. That's not what investors generally want to see. With revenue in decline, and profit but a dream, we can understand why t
Show less
Read more
Impact Snapshot
Event Time:
LAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LAB alerts
High impacting Standard BioTools Inc. news events
Weekly update
A roundup of the hottest topics
LAB
News
- Spatial Proteomics Market Projected to Reach USD 264.89 Million by 2032, Driven by a Strong 14.6% CAGR | Polaris Market Research [Yahoo! Finance]Yahoo! Finance
- Standard BioTools Appoints Alex Kim as Chief Financial OfficerGlobeNewswire
- Earnings Release: Here's Why Analysts Cut Their Standard BioTools Inc. (NASDAQ:LAB) Price Target To US$3.17 [Yahoo! Finance]Yahoo! Finance
- Standard BioTools Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Standard BioTools Inc. (NASDAQ: LAB) had its price target lowered by analysts at TD Cowen from $2.75 to $2.50. They now have a "buy" rating on the stock.MarketBeat
LAB
Earnings
- 10/30/24 - Beat
LAB
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/12/24 - Form 144
- LAB's page on the SEC website